Development and validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire

Juniper, Elizabeth F.; Thompson, Ann; Ferrie, Penelope J.; Roberts, Jeremy

doi:10.1046/j.1365-2222.2000.00668.x

Cited by 267 publications

(242 citation statements)

References 15 publications

Supporting

Mentioning

229

Contrasting

Unclassified

Order By: Relevance

“…18 A baseline disease-specific Rhinitis Quality-of-Life Questionnaire (RQLQ) was completed before swab or lavage collection each time. 19 Subjects went home with diary cards on which to record nasal symptoms twice daily when the allergy season began, as in prior work. 18 We used the diaries to rank four symptoms (sneezing, runny nose, nasal congestion, and other symptoms) on a scale of 0 to 3 (0 ϭ no symptoms and 3 ϭ severe symptoms).…”

Section: Subjectsmentioning

confidence: 99%

Seasonal Allergic Rhinitis Affects Sinonasal Microbiota

Choi¹,

Poroyko

Watanabe

et al. 2014

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

Section: Subjectsmentioning

confidence: 99%

Seasonal Allergic Rhinitis Affects Sinonasal Microbiota

Choi¹,

Poroyko

Watanabe

et al. 2014

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

“…Other nasal and ocular rhinitis symptoms -such as nasal itchingalso play a role in awakening patients. 21,22 In a recent survey of 2,355 individuals with self-reported AR in the United States, nasal congestion affected 80% or more of respondents in some way at night, causing them to wake up or making it difficult to fall asleep. 20 The effect of nasal congestion on sleep increased as the severity of congestion intensified.…”

mentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

“…Although this is a useful tool for group studies such as clinical trials and cross-sectional surveys, the standardised version is considered to be more sensitive for use in clinical practice [36].…”

Section: ) Generic Questionnairesmentioning

confidence: 99%